How were (KYTH)'s earnings last quarter?

(KYTH) (NASDAQ:KYTH) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.34. The biopharmaceutical company had revenue of $288 million for the quarter.

What other stocks do shareholders of (KYTH) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (KYTH) investors own include Bausch Health Companies (BHC) , Gilead Sciences (GILD) , (RPTP) (RPTP) , Altaba (AABA) , Intercept Pharmaceuticals (ICPT) , Incyte (INCY) , NPS Pharmaceuticals (NPSP) , OPKO Health (OPK) and Puma Biotechnology (PBYI) .

NASDAQ:KYTH

(KYTH) (KYTH) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free KYTH Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: N/A
50-Day Range: $0.09
▼
$0.09
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get (KYTH) alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About (KYTH) Stock (NASDAQ:KYTH)

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

KYTH Stock News Headlines

April 4, 2024 | msn.com

Glare from car headlights can be a killer – Scotsman comment

April 3, 2024 | msn.com

Casino chips ‘stealthily’ disappear from Tropicana Las Vegas before final closure

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 3, 2024 | msn.com

Resilience in the Face of Adversity Taiwan’s Response to the Strong Earthquake and Tsunami Threat

March 27, 2024 | msn.com

Rebecca Kenna on testing two years on tour: 'It's helped me as a person and a player'

March 26, 2024 | msn.com

The best asparagus you've ever made is topped with garlic and cheese. Here's how to make it

January 10, 2024 | morningstar.com

Agro Capital Management Corp ACMB

December 4, 2023 | msn.com

Xponential Fitness to acquire Lindora

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

December 4, 2023 | msn.com

RCI Hospitality declares $0.06 dividend

November 26, 2023 | msn.com

Bowl Projections: Huge favorite emerges as Tennessee’s destination

November 9, 2023 | morningstar.com

eXp World Holdings Inc 44Y

September 14, 2023 | msn.com

PBA draft a rich harvest

May 13, 2023 | msn.com

Just a fraud heads-up: I received a recorded message claiming to be from my bank’s fraud protection line.

April 14, 2023 | msn.com

Screaming people and bodies everywhere: The horrific aftermath of Myanmar junta airstrike that killed 165

April 12, 2023 | msn.com

Screaming people and bodies everywhere: The horrific aftermath of Myanmar junta airstrike that killed 133

April 12, 2023 | msn.com

Screaming people and bodies everywhere: The horrific aftermath of Myanmar junta airstrike that killed 100

March 31, 2023 | msn.com

Billionaire LeBron James REJECTS Elon Musk's $8 fee for a blue tick

March 7, 2023 | msn.com

Morocco, Credible Strategic Partner for France and EU (French MP)

December 28, 2022 | msn.com

WI Attorney General to focus fighting crime, ensuring public safety and protecting kids in 2023

November 5, 2022 | msn.com

Animals dream too—here's what we know

October 9, 2022 | msn.com

World Mental Health Day 2022: 81% school students anxious about studies and exam results, shows NCERT survey

October 8, 2022 | msn.com

Woman and baby boy found dead in house in Dublin

September 13, 2022 | msn.com

Afternoon brief: Karnataka minister sets Bengaluru demolitions timeline and all the latest news

September 1, 2022 | msn.com

DA nominates three retired judges for Ramaphosa’s Phala Phala inquiry

March 22, 2022 | msn.com

2 teachers stabbed to death by student at Sweden school

August 25, 2021 | msn.com

Sharing Chinese Herbal Soups and Teas, Steeped in Tradition

See More Headlines

Receive KYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KYTH) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/06/2015
Today: 4/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:KYTH
CUSIP: 50157010
CIK: 1436304
Web: N/A
Phone: +1-818-5874500
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

KYTH Stock Analysis - Frequently Asked Questions

How were (KYTH)'s earnings last quarter?: (KYTH) (NASDAQ:KYTH) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.34. The biopharmaceutical company had revenue of $288 million for the quarter.
What other stocks do shareholders of (KYTH) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other (KYTH) investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), (RPTP) (RPTP), Altaba (AABA), Intercept Pharmaceuticals (ICPT), Incyte (INCY), NPS Pharmaceuticals (NPSP), OPKO Health (OPK) and Puma Biotechnology (PBYI).

This page (NASDAQ:KYTH) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

(KYTH) (KYTH) Stock Price, News & Analysis

About (KYTH) Stock (NASDAQ:KYTH)

KYTH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

KYTH Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info